Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
Category: Health Insurance and Managed Care
-
Dr. Oz: How His Millions Collide With Medicare
The TV celebrity and Trump nominee has pledged to divest from most of his financial interests. But they touch nearly every corner of health care, from insurance to blood pressure cuffs and vitamins, leading experts and lawmakers to doubt he could make impartial decisions.
-
Chinese Hospital Bankruptcies Soar Amid Financial Strains
Still recovering from heavy spending during the pandemic, hospitals are squeezed by a slumping economy and government efforts to curb health care spending.
-
Oz, Trump’s Medicare Nominee, Pledges to Divest Interests in Health Care Stocks
The celebrity doctor said he would divest from his interests in many drug, medical and insurance companies, worth millions of dollars.
-
Medicare Doesn’t Pay for Everything: How to Bridge the Cost Gap
Older Americans have ways to protect against high out-of-pocket health care costs, but it’s important to understand the trade-offs.
-
How to Use an HSA to Save a Lot
A new analysis finds that a diligent saver who leaves the money untouched for decades can accumulate $1 million. But not everyone with an H.S.A. can afford to leave the money untapped.
-
In China, Rare Dissent Over a Program to Save on Drug Costs
Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.
-
UnitedHealthcare Announces New C.E.O.
The health insurer named Tim Noel, a longtime employee of its parent company, for the job. The previous chief executive, Brian Thompson, was killed in Manhattan.
-
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
-
UnitedHealth’s Revenues Rise, in First Earnings Report Since CEO’s Killing
But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.
-
Insulin Prices Dropped. But Some Poor Patients Are Paying More.
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for low-income health clinics.